

Special Issue

Nontraditional Antibiotics—Challenges and Triumphs, 2nd Volume

Message from the Guest Editor

The first volume of the Special Issue “Nontraditional Antibiotics—Challenges and Triumphs” was published in 2019. It was a successful issue with nine published papers, encouraging us to open a second volume with the same topic. This second volume aims to complement the 2019 Special Issue and invites submissions that highlight the current advances supporting the development and application of nontraditional antibiotic therapies. Topics may include but are not limited to:

- Antibodies, including antibody/antibiotic conjugates;
- Bacteriophages and lysins;
- Microbiome modulation;
- Narrow spectrum agents;
- Antibiotic potentiators and inactivators;
- Antimicrobial and immunomodulatory peptides;
- Biofilm disruptors;
- Virulence modulators;
- Targeted degradation approaches.

Guest Editor

Dr. Karl Hansford

Institute for Molecular Bioscience, University of Queensland, Brisbane, QLD 4072, Australia

Deadline for manuscript submissions

closed (31 December 2022)



Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



mdpi.com/si/89280

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)





Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of
Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)